Samsung Bioepis, Takeda collaborate on severe pancreatitis therapy

11:04 EDT 21 Aug 2017 | Healio

Samsung Bioepis has joined with Takeda to develop multiple novel biologic therapies, including the collaboration’s first therapeutic candidate, TAK-671 for severe acute pancreatitis, according to a press release.“Takeda’s extensive knowledge and expertise in drug development makes the company an ideal partner for us as we open a new chapter at Samsung Bioepis,” Christopher Hansung Ko, president and CEO of Samsung Bioepis, said in the release. “Together with Takeda, we look forward to realizing this vision by accelerating the development of effective therapies for patients who are currently without a viable treatment option.”

Original Article: Samsung Bioepis, Takeda collaborate on severe pancreatitis therapy


More From BioPortfolio on "Samsung Bioepis, Takeda collaborate on severe pancreatitis therapy"

Quick Search


Relevant Topics

Mergers & Acquisitions
Commercial and market reports on mergers and acquisitions in the biotechnology, pharmaceutical, medical device and life-science industries. Mergers and acquisitions (abbreviated M&A;) is an aspect of corporate strategy, corporate finance and manageme...

Astroesophageal Reflux Disease (GERD) Barrett's Esophagus Celiac Disease Cholesterol Crohn's Disease Gastroenterology Hepatitis Hepatology Irritable Bowel Syndrome (IBS) Pancreatitis Peptic Ulcer Disease...